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The substantial augmentation of the radiation sequelae during chemo–radiotherapy with novel drugs masks the real potential
of such regimens. In this study we examined whether subcutaneous administration of amifostine can reduce the toxicity of a
highly aggressive chemo–radiotherapy scheme with Stealth
Ò liposomal doxorubicin (Caelyx
Ò) and Docetaxel (Taxotere
Ò)i n
non-small cell lung cancer. Twenty-ﬁve patients with stage IIIb non-small cell lung cancer were recruited in a phase I/II dose
escalation trial. The starting dose of Taxotere
Ò was 20 mg m
72 week and of Caelyx
Ò was 15 mg m
72 every two weeks,
during conventionally fractionated radiotherapy (total dose of 64 Gy). The dose of Taxotere
Ò/Caelyx
Ò was, thereafter,
increased to 20/25 (ﬁve patients) and 30/25 mg m
72 (15 patients). Amifostine 500 mg was given subcutaneously before each
radiotherapy fraction, while an i.v. amifostine dose of 1000 mg preceded the infusion of docetaxel. The ‘in-ﬁeld’ radiation
toxicity was low. Grade 3 esophagitis occurred in 9 out of 25 (36%) patients. Apart from a marked reduction of the
lymphocyte counts, the regimen was deprived from any haematological toxicity higher than grade 1. No other systemic
toxicity was noted. The CR and CR/PR rates in 15 patients treated at the highest dose level was 40% (6 out of 15) and 87%
(13 out of 15) respectively. It is concluded that the subcutaneous administration of amifostine during high dose Taxotere
Ò/
Caelyx
Ò chemo–radiotherapy is a simple and effective way to render this aggressive regimen perfectly well tolerated, by
reducing the systemic and the ‘in-ﬁeld’ toxicity to the levels expected from simple conventional radiotherapy. The impressive
tolerance and the high CR rate obtained encourages the conduct of a relevant randomized trial to assess an eventual survival
beneﬁt in patients with non-small cell lung cancer.
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Non-small cell lung cancer (NSCLC) is a major cause of death
from cancer. Even in early stages of the disease 30–50% of patients
will relapse locally or to distant organs following surgery (Kayser et
al, 1987). Radiotherapy is the treatment of choice in locally
advanced inoperable cases but the results are frustrating as the cure
rate is less than 10% (Koukourakis et al, 1996). Accelerated and/or
hyperfractionation techniques may increase the local control rate
by 10–20% (Saunders et al, 1996). Concurrent platinum based
chemo–radiotherapy showed improved efﬁcacy in randomized
studies (Marino et al, 1995; Schaake-Koning et al, 1992; Jeremic
et al, 1996), while in a recent study by Furuse et al (1999) the
concurrent approach yielded enhanced median survival duration
in selected patients with unresectable stage III NSCLC.
Several novel anti-cancer drugs have shown important radiosen-
sitizing properties in vitro (Hennequin et al, 1996; Tamura et al,
1997; Milas et al, 1999), which encourages clinical trials of
chemo–radiotherapy. In phase I/II trials, both paclitaxel and doce-
taxel showed a high rate of complete responses in locally advanced
NSCLC (Reckzeh et al, 1996; Koukourakis et al, 1998a). However,
severe mucositis and immunological toxicity accompanied these
regimens (Koukourakis et al, 1999a). A novel antimetabolite,
Gemcitabine, has shown remarkable activity against NSCLC and
important radiosensitizing properties (Milas et al, 1999). Clinical
trials, however, suggest that substantial reduction on the gemcita-
bine dose should be considered in order to have acceptable
toxicity (Eisbruch et al, 2001; Trodella et al, 2002). Combination
of low dose of camptothecines with radiotherapy also results in a
very high mucosal toxicity (Graham et al, 1996). Severe mucositis
is also the dose limiting toxicity of the combination of radiother-
apy with liposomal doxorubicin (Koukourakis et al, 1999b).
The dramatic augmentation of the radiation sequelae during
chemo–radiotherapy with all these novel compounds masks the
real potential of such regimens as (1) only a reduced dose of the
chemotherapeutic agent can be safely administered during radio-
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radiotherapy failure as unnecessary delays of the schedule are
enforced due to severe toxicity and, (3) combination of more than
one of these drugs with radiotherapy is expected to be problematic.
Unless effective and selective cytoprotection of normal tissues
increases the tolerance, these novel and potentially highly effective
chemo–radiotherapy regimens will not ﬁnd their place in the clin-
ical practice.
In the present dose escalating study we show that standard
radiotherapy can be safely combined with high doses of two drugs,
namely Stealth
Ò liposomal doxorubicin (Caelyx
Ò) and Docetaxel
(Taxotere
Ò), if subcutaneous amifostine is used as a broad spec-
trum cytoprotective agent (Koukourakis et al, 2000a).
PATIENTS AND METHODS
Recruitment criteria
Patients with histologically-conﬁrmed inoperable (stage IIIb; T3,4-
N2,3-M0) NSCLC entered this phase I/II study. All patients had
disease inﬁltrating the thoracic wall, trachea, thoracic vessels and
pericardium, and/or presence of contralateral mediastinal and/or
supraclavicular involved nodes. Patients with white blood cells
52500 ml
71 and platelets 5120000 ml
71 were excluded. Patients
with haemoglobin 510 g dl
71 were transfused until haemoglobin
levels were raised 412 g dl
71. Pregnant women or patients with
major heart, lung, liver, renal, psychiatric disease, or with haema-
tological malignancies were excluded. Written informed consent
was obtained from all patients. The study was approved by the
local Oncology Trial Committee.
Pretreatment and treatment evaluation
Baseline studies included physical examination, chest X-rays,
whole blood count with differential and platelet count,
complete biochemical proﬁle, bone scan and computed tomo-
graphy (CT-scan) of the chest and upper abdomen. Whole
blood cell count was performed once a week during the radio-
therapy period and for 4 weeks thereafter. Serum urea and
creatinine, as well as liver enzymes were analysed every 2
weeks during radiotherapy. Electrocardiograms were performed
every 3 weeks. Acute radiation toxicity was registered twice
weekly. The World Health Organization (WHO) scale was used
to assess chemotherapy and acute radiation toxicity (World
Health Organization, 1979).
Response to treatment was assessed with a CT-scan on day 25
(to allow eventual modiﬁcation of the radiotherapy ﬁelds) and
45–60 days following treatment completion. Complete response
(CR) was deﬁned as the disappearance of a measurable lesion with-
in 2 months following treatment completion, lasting for at least 2
months after response documentation. Remnant scar on CT-scan
measuring less than 5% of the initial tumour volume and showing
no signs of progression within 2 months after response documenta-
tion was considered as complete response. Similarly, partial and
minimal response (PR and MR) was deﬁned as a 50–95% and
25–49% reduction in tumour size, respectively. Smaller reductions
in tumour size (0–24%) that lasted at least 2 months after
response documentation were considered stable disease (SD). All
other cases were considered progressive disease (PgD), regardless
of the initial response.
The duration of response was measured from the time the
criteria for the objective response were ﬁrst met. CT-scan done
every 2 months for the ﬁrst 6 months and every 3 months (or
earlier if necessary) thereafter. The patients were followed with
clinical examination and haematological and biochemical tests once
every 2 months. Bone scan or computed tomography other than
chest was performed when indicated by speciﬁc symptomatology.
For late radiation sequelae the RTOG scale was used (RTOG late
effects working group, 1995).
Radiotherapy schedule
Radiotherapy treatment planning was based on chest CT-scans. A
6MV LINAC (Philips) was used to treat all patients. Anteroposter-
ior radiation portals encompassing the primary tumour area and
part of the mediastinum were used to deliver a daily dose of
2 Gy, up to 44 Gy. In patients with upper lobe tumours, the lower
margine of the mediastinal ﬁelds were placed 6 cm below the cari-
na, while the upper margin was extended to include the homolateral
supraclavicular area. In patients with lower lobe tumours, the upper
limit of the mediatinal ﬁeld was placed to the sterno–clavicular
joint level. One or two oblique ﬁelds directed to the bulky tumour
area were thereafter used to increase the total tumour dose to 64 Gy
(dose per fraction 2 Gy). The planned overall treatment time was
6.5 weeks. No conformal techniques were used.
Chemo–radiotherapy combination and dose escalation
The chemo–radiotherapy scheme used is diagrammatically
reported in Table 1. Docetexel (Taxotere
Ò) was given every
Monday, once weekly during the seven consecutive weeks of radio-
therapy. Stealth liposomal doxorubicine (Caelyx
Ò) was given every
other Monday, once every 2 weeks (1st, 3rd, 5th and 7th week of
radiotherapy). The starting dose of Taxotere
Ò/Caelyx
Ò regimen was
20/15 mg m
72. Five patients were recruited in this dose level. The
dose of the drugs was escalated in two higher dose levels:20/25
and 30/25 mg m
72 (ﬁve patients in each dose level). The Taxo-
tere
Ò dose of 30 mg m
72 week and the Caelyx
Ò dose of
25 mg m
72 every 2 weeks were the maximum tolerated doses
identiﬁed in previously conducted chemo–radiotherapy dose esca-
lation studies (Koukourakis et al, 1998a; 1999b). No further
escalation beyond this ‘maximum dose level’ was to be tried. Once
the MTD (or the maximum dose level) would have been achieved,
the study was to continue as a phase II one to assess response and
toxicity of the proposed schedule in a cohort of 15 patients.
Taxotere
Ò and Caelyx
Ò administration procedure
Twelve hours and 30 min before chemotherapy patients received
32 mg p.o. and 125 mg i.v. bolus methyl-prednisolone, respec-
tively. Ranitidine 300 mg p.o. was given daily throughout the 6
week treatment. Tropisetron (10 mg i.v.) was given as antiemetic
treatment. Taxotere
Ò was diluted in 250 ml normal saline and
infused within 20 min. Blood pressure and symptomatology assess-
ment was monitored every 5 min during infusion and every
15 min for the following hour. No steroids were used thereafter
if no allergic reaction occurred. Whenever allergic reaction was
observed patients were given methyl-prednisolone (32 mg p.o.)
12 h after chemotherapy.
Caelyx
Ò was diluted in 250 ml distilled water and infused within
30 min. Blood pressure was monitored and symptoms were
assessed every 5 min during infusion and every 15 min for the
following hour.
Administration of amifostine
During the days of chemo–radiotherapy (Mondays), amifostine
was given intravenously immediately before docetaxel. Amifostine
(Ethyol
Ò), 1000 mg diluted in 50 ml normal saline, was infused
within 5 min, the patient being in a supine position, and under
continuous monitoring of blood pressure. Docetaxel administra-
tion began 10 min after the amifostine infusion.
During the days of radiotherapy (Tuesday to Friday), amifostine
was given subcutaneously, as previously described (Koukourakis et
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(Navoban
Ò, Novartis) 1–2 h before the subcutaneous injection of
amifostine. Amifostine (500 mg ﬂat dose) was diluted in 2.5 ml
normal saline and was injected subcutaneously to the shoulder or
abdominal area. The injection was repeated daily, 20 min before
each radiotherapy fraction. Amifostine was injected with the
patient being in a sitting position. Blood pressure monitoring
(before and after injection) was performed once every week.
Toxicities, treatment modiﬁcation and supportive care
In case of grade 3/4 non-haematological toxicity, the dose of
Caelyx
Ò or Taxotere
Ò was reduced by 50% or chemotherapy was
interrupted, depending on severity of the adverse effect. Grade 2
neutropenia was to be immediately followed by GM–CSF support
(400 mg s.c. every Saturday and Sunday). This supportive regimen,
established in previously published studies of ours (Koukourakis et
al, 1998b, 2001), effectively protected from neutropenia patients
receiving concurrent chemo–radiotherapy using a high dose of
carboplatin fractionated regimen or docetaxel/carboplatin
chemotherapy. In the present study, the adoption of this GM–
CSF regimen immediately following the documentation of a grade
2 neutropenia, would potentially allow the elimination of neutro-
penia as a dose limiting toxicity factor.
All types of severe non-haematological ‘in ﬁeld’ chemo–radio-
therapy related toxicities such as grade 3 mucosal (esophageal or
oral/pharyngeal) toxicity, extensive ‘in-ﬁeld’ moist skin desquama-
tion with ulceration, severe pain or exertional dyspnea were to be
followed by radiotherapy and chemotherapy interruption till recov-
ery (regression of symptomatology to grade 1). Patients with
mucositis were supported with non-steroid anti-inﬂammatory regi-
men (mainly nimesulide) and prophylactic oral anti-fungal
therapy. Acute radiation pneumonitis was treated with antibiotics
and steroids if that was deemed necessary. Any infection was trea-
ted with appropriate antibiotic therapy. Severe asthenia was
followed by interruption of both radiotherapy and chemotherapy
till recovery.
Caelyx
Ò- and Taxotere
Ò- related severe non-haematological
toxicities (outside the radiation ﬁeld) such as pneumonitis, severe
erythrodysesthesia, severe allergic reactions or other less frequently
expected complications were followed by chemotherapy interrup-
tion and treatment continuation with radiotherapy alone.
Deﬁnition of the maximum tolerated dose
When in a cohort of patients three out of ﬁve of them expressed
severe ‘in ﬁled’ non-haematological toxicity that necessitated more
than 1 week radiotherapy delay, the toxicity was considered as dose
limiting (DLT). Similarly, haematological grade 3/4 toxicity in a
cohort of three out of ﬁve cases (despite the support with GM–
CSF) or other severe non-haematological drug related toxicity in
at least three out of ﬁve patients also deﬁned a DLT. The Taxo-
tere
Ò/Caelyx
Ò dose level immediately before the level where the
DLT was observed, was the maximum tolerated dose (MTD). In
this dose level a total of 15 patients were to be recruited.
Statistical analysis
The statistical analysis and graph presentation of survival curves
was performed using the GraphPad Prism 2.01 (GraphPad
Ò, San
Diego, CA, USA, www.graphpad.com) package. Survival curves
were plotted using the method of Kaplan and Meier. The Fisher’s
exact test or the unpaired two-tailed t-test was used to test differ-
ences between categorical variables as appropriate. A P-value
50.05 was used for signiﬁcance.
RESULTS
Twenty-ﬁve patients were recruited in the study. Five in dose level
1, ﬁve in dose level 2 and 15 in dose level 3, which was the target
dose level . Table 2 shows the patients characteristics. Twenty-four
had evaluable disease on CT-scan, while one had known residual
(non-measurable) disease after incomplete surgery.
Systemic toxicity of chemotherapy
In all three dose levels, the Taxotere
Ò/Caelyx
Ò chemotherapy
combination showed an excellent tolerance. Grade 1 neutropenia
was noted in ﬁve out of 15 patients treated in the 3rd dose level.
Grade 2–4 neutropenia was not noted in the 25 treated patients,
so that GM–CSF was not used. Grade 2 anaemia was noted in
one out of 10 and two out of 15 patients in the 1st–2nd and
the 3rd dose level. Patients were transfused with red cells till the
Hb levels reached values 411 gr dl
71. No platelet toxicity was
observed. The lymphocyte counts dropped from 1241+307 dl
71
down to 782+390 dl
71 during the 3rd week and to 749+245
during the 6th week of treatment.
Mild grade 1 palmar-plantar erythrodysesthesia related to
Caelyx
Ò was noted in two out of 15 patients treated in the 3rd
dose level. Alopecia grade 1 was noted in 24 out of 25 and grade
2 in one out of 15 (3rd dose level) patients. No case of peripheral
docetaxel related neuropathy, pulmonary, cardiac or renal toxicity
was noted.
‘In-ﬁeld’ toxicity
The main expected ‘in ﬁeld’ acute non-haematological toxicity of
the combination was esophageal mucositis. Grade 3 dysphagea
appeared during the 3rd–4th week in two out of ﬁve, one out
of ﬁve and two out of ﬁve patients in the three dose levels,
respectively. Radiotherapy was interrupted and esophagitis
regressed to grade 0/1 within 3–7 days in all patients. Two
patients (one in the 1st and one in the 3rd dose level) showed
fungal infection and were treated with oral ﬂuconazole (100 mg
three times-a-day for 7 days). None of the patients developed
higher than grade 1 skin toxicity and there was no case with
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Table 1 The chemo–therapy scheme used in the present study
Week 1 Week 2
MT W TF S S MT W TF S S
RT (Gy) 2 2 2 2 2 2 2 2 2 2
Ethyol
Ò s.c. (mg) – 500 500 500 500 – 500 500 500 500
Ethyol
Ò i.v. (mg) 1000 – – – – 1000 – – – –
Taxotere
Ò (*) – – – – (*) – – – –
Caelyx
Ò ( * )–––– – ––––
GM–CSF (**) mg – –––– 4 0 0 – –––– 4 0 0
(*) dose (mg m
72) escalation (Taxotere/Caelyx): level 1 20/15, level 2 20/25, level 3 30/25. (**) only after the documentation of grade 2 neutropenia.
Taxotere
Ò/Caelyx
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rare during chest radiotherapy, was not observed in any of the
patients.
As both systemic and ‘in-ﬁeld’ toxicity were minor in the 3rd
dose level, recruitment of patients in this latter level continued
to reach a total of 15 patients. Grade 3 esophagitis appeared in
six out of 15 (40%) patients, in four of which there was a super-
imposed fungal infection. A split of chemo–radiotherapy of 1
week was inserted for these patients. In four (26%) of these
patients, esophagitis regressed to grade 1 following a 7-day radio-
therapy split, while in the remaining two (13%) patients (both
with fungal infection) an 8–14 day split was necessary. No other
‘in-ﬁeld’ toxicity higher than grade 1 was noted. Although the dose
limiting toxicity was not reached in the 3rd dose level, no further
escalation of the dose of chemotherapy was attempted.
Within 18–24 months of follow-up, CT-scan ﬁndings of ‘in-
ﬁeld’ radiation lung ﬁbrosis were detected in seven out of 25
(28%) patients but, there was not a case with symptomatic exer-
tional dyspnea requiring oxygen support. No patient developed
radiation-related soft tissue, neurological or cardiac late sequelae.
Amifostine tolerance
Local subcutaneous injection of amifostine was associated with
mild local pain, while extensive local erythema, necessitating the
changing of multiple sited injections and local application of ster-
oid cream, was experienced in one out of 25 patients (4%). Grade
2 nausea due to s.c. injection of amifostine was noted in two out of
25 (8%) patients. Hypotention was not observed in any of the 25
recruited patients. Of interest, the fever/rash symptomatology,
which occurs in 8% of patients receiving s.c. amifostine (Koukour-
akis et al, 2000a), was also unobserved.
The intravenous administration of amifostine was well tolerated,
with grade 2 nausea observed in three out of 25 (12%) of patients.
Using the administration procedure described, symptomatic hypo-
tention did not occur, but a signiﬁcant drop of the systolic blood
pressure to values 590 mm Hg, requiring 3–5 min infusion inter-
ruption (during one or more of the scheduled infusions) was
necessary in 12 out of 25 patients (48%). Asthenia grade 2
(whether related to docetaxel or amifostine) was observed in three
out of 25 (12%) patients. Therapy (chemotherapy and radiother-
apy) was interrupted for 1 week in one patient. The dose of
amifostine was reduced to 300 mg and two out of three patients
completed the scheduled therapy. One patient presented fever
(398C) after the 4th i.v. injection and amifostine was discontinued.
Comparative analysis of toxicity
The main in-ﬁeld and systemic toxicities recorded in this study
were comparatively analysed with the toxicities noted in three
previous studies of ours in patients with locally advanced NSCLC
treated with (1) conventionally fractionated chemo–radiotherapy
with weekly Taxotere
Ò 30 mg m
72 (Koukourakis et al, 1999c),
(2) conventionally fractionated chemo–radiotherapy with Caelyx
Ò
once every 2 weeks 25 mg m
72 (Koukourakis et al, 1999b) or, (3)
conventionally fractionated radiotherapy with and without subcu-
taneous administration of amifostine (Koukourakis et al, 2000a).
The analysis is reported in Table 3. Esophageal toxicity was
impressively reduced. Esophagitis enforcing more than 1 week
delay of radiotherapy was noted in 23–33% of patients treated
with RT+Taxotere or RT+Caelyx without amifostine vs 12% in
patients treated with RT alone vs 8–13% of patients treated with
RT+Taxotere+Caelyx supported with amifostine.
Despite the administration of docetaxel, a drug associated with
high incidence of profound asthenia, the asthenia noted in the
present study was reduced compared to the docetaxel/RT study
(12 vs 23% grade 2 asthenia). The typical fever/rash amifostine
related symptomatology, noted in 10% of NSCLC patients treated
with standard RT and s.c. administered amifostine was absent,
although one patient presented fever without rash and amifostine
administration was interrupted.
No grade 2 neutropenia has been observed, compared to the
20% rate expected. Three and 6 weeks following the beginning of
radiotherapy, the mean lymphocyte counts of patients in the
present study were signiﬁcantly higher compared to the ones
recorded in the phase II study of Taxotere
Ò and radiotherapy with-
out amifostine (3rd week: 782+390 vs 589+297, P=0.009 and 6th
week: 741+243 vs 354+93; P=0.0001). Figure 1 shows the
lymphocyte counts obtained in the two studies.
Response and outcome
Table 4 shows the responses observed, 2 months following RT,
stratiﬁed by dose level. Complete response of the chest disease
was observed in nine out of 24 (37.5%) and partial response in
nine out of 24 (37.5%) evaluable cases, the total response rate
being 75%. The overall response rate in the 3rd dose level was
87% (40% CR and 47% PR). Figure 2 shows the CT-scan of a large
lung squamous cell carcinoma before therapy and its complete
remission 2 months following the end of treatment.
The efﬁcacy of the present schedule in terms of responses
obtained compares favourably to previous regimens (Table 3).
The criteria used for recruitment of patients in the present study
were the same used in these historical studies and age, performance
status and disease stage of patients recruited are similar in all
studies reported in Table 3. Both the complete and the combined
complete/partial response rates were signiﬁcantly higher compared
to the responses obtained in a previous study in locally advanced
NSCLC treated with radiotherapy alone (CR 40 vs 4%; P=0.003
and CR/PR 87 vs 20%; P=0.0001) or with radiotherapy supported
with subcutaneous amifostine administration (CR 40 vs 7%;
P=0.01 and 87 vs 33%; P=0.001). The response rates were compar-
able to the ones obtained in a previous study on docetaxel chemo–
radiotherapy and slightly higher than the ones obtained in a study
with liposomal doxorubicine chemo–radiotherapy.
After 18–24 months of follow-up, seven (28%) patients are still
alive with no evidence of local or distant disease. Eight patients
died due to local progression, two of which had also distant metas-
tases. Overall nine patients expressed distant metastases. One
patient died due to the development of malignant pericardial effu-
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Table 2 Patient and disease characteristics
NSCLC
Number of patients 25
Age (years, mean, range) 68 (45–78)
Sex
Male/Female 25/0
Performance status
WHO 0,1 21
WHO 2 4
Histology
squamous cell 22
adenocarcinoma 3
Stage
T3,4-N2,3-M0 (IIIb) 25
Previous surgery 1
Previous chemotherapy
none 19
pretreated 6
taxane-based 4
platinum-based 5
doxorubicin-based 1
Taxotere
Ò/Caelyx
Ò chemo–radiotherapy in NSCLC
MI Koukourakis et al
388
British Journal of Cancer (2002) 87(4), 385–392 ã 2002 Cancer Research UKsion immediately after therapy, and one due to pulmonary embo-
lism 1 month following treatment completion.
Figure 3 shows the Kaplan–Meier survival curves of overall
survival, local progression free survival and distant metastasis-free
survival. The median survival was 9 months.
DISCUSSION
The results of radiotherapy for inoperable non-small cell lung
cancer (NSCLC) are frustrating. Concurrent or induction
chemotherapy slightly improves the ﬁgures; median survival is
marginally improved in randomized trials (Marino et al, 1995).
Combination of novel drugs with radiotherapy is an interesting
and promising ﬁeld of clinical research. However, radiation toxicity
becomes unacceptably high and may jeopardize the outcome of
eventual phase III trials investigating such combinations. The estab-
lishment of well tolerated chemo–radiotherapy schemes is therefore
essential before the initiation of randomized trials aiming to estab-
lish new standards for the treatment of locally advanced carcinomas.
In a previous randomized phase II study, we found that a simple
subcutaneously administered schedule of amifostine signiﬁcantly
protected normal mucosa against radiation and prevented unneces-
sary delays that compromise the efﬁcacy of radiotherapy
(Koukourakis et al, 2000a). In the present study we investigated
whether this broad-spectrum cytoprotective regimen can improve
the tolerance of concurrent chemo–radiotherapy with high doses
of two novel drugs (Taxotere
Ò and Caelyx
Ò) for NSCLC. Both
drugs have important radiosensitizing properties. Taxanes induce
synchronization of cancer cells to the radiosensitive G2/M phase
of the cell cycle (Walf et al, 1996) and, furthermore, induce phos-
phorylation of the anti-apoptotic bcl-2 protein, which enhances
radiation apoptosis (Haldar et al, 1996; Beham et al, 1998). Stealth
liposomal doxorubicin is preferentially accumulated into the
tumoural environment (Stewart and Harrington, 1997; Yuan et
al, 1994; Harrington et al, 2001a) and the free-doxorubicine
released has both cytotoxic and radiosensitizing properties (Bonner
and Lawrence, 1990; Harrington et al, 2000). Moreover, the taxanes
may further sensitize cancer cells to a DNA damaging agents, such
as doxorubicine. In this way, multiple radio- and chemo- sensitiza-
tion expected with such a regimen may result to an increased anti-
tumour effect but, also to an increased toxicity.
In previous phase I/II studies we established the MTD of each one
of these drugs for combination with radiotherapy (Koukourakis et
al, 1998a, 1999a,b,c). Mucosa toxicity was high and unnecessary
splits of radiotherapy were enforced, which may have reduced the
efﬁcacy of the regimens (Koukourakis et al, 1999c). In the present
study, pre-treatment of patients with subcutaneous amifostine
allowed the administration of full dose of both drugs in combina-
tion with conventionally fractionated radiotherapy. Comparative
analysis of the mucositis observed in the present and in previous
chemo–radiotherapy studies conducted with the same drugs but
without amifostine, showed that the mucositis induced after high
dose concurrent chemo–radiotherapy supported with subcutaneous
amifostine is impressively reduced close to the one expected from
standard radiotherapy alone. These results are encouraging as muco-
sitis is the dose-limiting toxicity encountered in novel chemo–
radiotherapy combinations and subcutaneous amifostine may there-
fore be a key for the succesful application of these novel regimens.
Similarly low was the incidence of acute radiation pneumonitis,
which is quite common when radiotherapy is combined with
taxanes (Reckzeh et al, 1996; Koukourakis et al, 1999c). Amifostine
is well known to protect against radiation pneumonitis (Antona-
dou et al, 2001; Komaki et al, 2001). Skin toxicity was also low.
These results, apart from conﬁrming the important cytoprotective
efﬁcacy of amifostine, also eliminate worries on potential enhanced
toxicity due to an eventual increased biodistribution of liposomal
doxorubicine in irradiated normal tissues. Changes in vascular
permeability and integrity induced by radiotherapy could result
in increased accumulation of liposome within the irradiate lung,
skin or muscles and end to destructive complications. Harrington
et al, however, showed that radiotherapy does not change the
normal tissue biodistribution and pharmacokinetics of liposomal
doxorubicine, suggesting that combination of the drug with radia-
tion should be safe (Harrington et al, 2001a,b). Indeed, the
patterns of toxicity noted in the present study and in previous
studies of ours (Koukourakis et al, 1999b, 2000b) combining
Caelyx
Ò with radiotherapy conﬁrm that such regimens are safe
for patients. Amifostine further improves the tolerability of such
chemo–radiotherapy combinations.
Of interest, the incidence of asthenia, which is a main complica-
tion of docetaxel combination with radiotherapy was reduced. In
previous studies we suggested that the intense immunosuppression
related to docetaxel chemo–radiotherapy accounts for the asthenia
of treated patients (Koukourakis et al, 1998a, 1999c). Protection of
amifostine against immunological toxicity may therefore account
for the reduced incidence of asthenia noted in the present study.
Indeed, the lymphocytic toxicity noted in the present study was
signiﬁcantly less profound that the one noted in previous studies
with docetaxel chemo–radiotherapy without amifostine.
Another provocative observation is that the fever/rash sympto-
matology related to amifostine, which is noted in 7–10% of
patients undergoing protracted subcutaneous amifostine adminis-
tration and consists a major cause of amifostine discontinuation
(Koukourakis et al, 2000a; Shaw and Bleakley, 2000), was not
observed in the present study. The fever/rash syndrome is not
related to increased IgE levels or eosinophil counts, while a 2–3-
fold increase of C-reactive protein is persistently noted in these
patients, suggesting a cytokine/monokine release triggered by
C
l
i
n
i
c
a
l
Table 3 Response of the primary tumour
Dose Taxotere
Ò/ CR PR MR SD-PgD NE(**)
Caelyx
Ò (%) (%) (%) (%) (%)
Dose (mg m
72) No pts
20/25 5 1 (20) 2 (40) 0 (0) 2 (40) 0
20/15 5 2 (50)* 0 (0) 2 (50)* 0 (0) 1
30/25 15 6 (40) 7 (47) 1 (6.5) 1 (6.5) 0
All levels 25 9 (37.5)* 9 (37.5)* 3 (12.5)* 3 (12.5)* 1
(*) Response rate (%) refers to evaluable cases. (**) NE=not evaluable.
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Figure 1 Comparative representation of the mean lymphocyte counts
(per dl) and standard deviation in locally advanced non-small cell lung can-
cer patients treated in the present study (radiotherapy with Taxotere
Ò/
Caelyx
Ò supported with amifostine) and in a previous phase II study of
radiotherapy and Taxotere
Ò (without amifostine).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(4), 385–392amifostine (Koukourakis et al, 2000a). Docetaxel chemotherapy or
chemo–radiotherapy is associated with a dramatic reduction of B-
cell, T-cell counts as well as natural killer counts (Koukourakis et
al, 1998a, 1999a; Kotsakis et al, 2000). It may be, therefore, that
the immunoreactive-cell count reduction induced by docetaxel
accounts for the fever/rash symptomatology elimination. Neverthe-
less, the once-a-week high dose of methylprednisolone
administered in the context of the pre-medication for the admin-
istration of docetaxel may also have contributed to cytokine
release suppression. This ﬁnding provides a rational for testing
whether steroids may improve the tolerance of subcutaneous
amifostine. Once-a-week methylprednisolone 32 mg per o.s. is
the suggested schedule of steroids. Our limited experience with
patients exhibiting poor tolerance of subcutaneous amifostine
(asthenia, vomiting) also shows that once-a-week injection of slow
release cortisone indeed improves tolerability (unpublished data).
Despite the relatively high dose intensity of Taxotere
Ò
(120 mg m
72 every 4 weeks) and of Caelyx
Ò (50 mg m
72 every
4 weeks), the combination of each one of these drugs separately
with radiotherapy results in a low neutrophil toxicity. The grade
2 neutropenia expected from Caelyx
Ò combination with radiother-
apy at this dose intensity is in the range of 20%. In the present
study, despite the double-chemotherapy scheme used together with
radiotherapy, there was not a case of grade 2 neutropenia. This
should be attributed to the protracted subcutaneous schedule of
amifostine. Caelyx
Ò has a long half-life of 92 h in the plasma, so
that the i.v. dose of amifostine given before Taxotere
Ò/Caelyx
Ò
infusion is unlikely to have protected the bone marrow from the
cytotoxicity of Caelyx
Ò. Indeed, in an experimental study in mice,
i.v. injection of 100 mg kgr of amifostine for four consecutive days
following the administration of liposomal doxorubicin, signiﬁcantly
reduced the rate of erythrodysesthesia without reducing the anti-
neoplastic activity of the drug (Lyass et al, 2001). Erythrodysesthe-
sia was negligible in the present study.
The response rate obtained was very high compared to the
expected from simple conventionally fractionated radiotherapy,
reaching 40% CR and 87% mixed CR and PR rates. However,
similar response rates are also expected following docetaxel
chemo–radiotherapy. Whether Taxotere
Ò/Caelyx
Ò chemo–radio-
therapy is superior to Taxotere
Ò chemo–radiotherapy is an issue
that cannot be answered by the present study. Nevertheless, the
excellent tolerance and the impressive CR rates obtained with this
double chemosensitization regimen, despite the large tumour
burden, provides the basis for subsequent relevant randomized
trials.
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Table 4 Comparative analysis of toxicity and of efﬁcacy of different regimens we used in phase II studies for the treatment of locally advanced non-small
cell lung cancer (NSCLC)
CFRT/Tax CFRT/Cae CFRT/Ami* CFRT
Present study (Koukourakis (Koukourakis (Koukourakis (Koukourakis
phase I phase I & II et al, 1999c) et al, 2000b) et al, 2000a) et al, 2000a)
Esophageal mucositis
RT split 58 days 4/15 (26%) 7/25 (28%) 8/35 (23%) 3/6 (50%) 8/19 (42%) 7/17 (41%)
RT split 8–14 days 2/15 (13%) 2/25 (8%) 8/35 (23%) 2/6 (33%) 1/19 (5%) 2/17 (12%)
Neutropenia
grade 2 0/15 (0%) 0/25 (0%) 2/35 (6%) 1/6 (18%) 0/19 (0%) 0/17 (0%)
Mean lymphocyte counts/dl
1st week 1241+307 – 1743+896
3rd week 782+390 – 589+297 – – –
6th week 741+243 – 354+93 – – –
Asthenia
grade 2 1/15 (7%) 3/25 (12%) 8/35 (23%) 0/6 (0%) 4/19 (21%) 1/17 (6%)
Fever/rash symptomology
yes 0/15 (0%) 1/25 (4%)** – – 3/19 (16%) –
Response rate
complete 6/15 (40%) 9/24 (37%) 12/35 (34%) 2/6 (33%) 2/18 (11%) 1/17 (5%)
complete+partial 13/15 (87%) 18/24 (75%) 28/35 (80%) 4/6 (66%) 10/18 (55%) 6/17 (35%)
CFRT: conventionally fractionated radiotherapy, Tax: docetaxel, Cae: stealth liposomal doxorubicibe, Ami: Amifositne. (*) Including patients that did not receive the scheduled
dose of Amifostine, (**) fever 398C without rash.
A
B
Figure 2 A CT-scan from a lung squamous carcinoma before (A) and
after the end (B) of Taxotere
Ò/Caelyx
Ò chemo–radiotherapy.
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British Journal of Cancer (2002) 87(4), 385–392 ã 2002 Cancer Research UKIt is concluded that the subcutaneous administration of amifos-
tine during high dose Taxotere
Ò/Caelyx
Ò chemo–radiotherapy is a
simple and effective way to render this aggressive regimen perfectly
well tolerated by reducing the mucosal toxicity to levels expected
from simple conventional radiotherapy. No haematological or
other systemic toxicity is expected. Randomized trials with this
promising double-radiosensitization regimen are warranted, to
assess an eventual survival beneﬁt in patients with inoperable
locally advanced non-small cell lung carcinoma. The dramatic
responses expected with such combinations also put forward an
eventual re-assessment of patients for surgery, which should be also
taken into account in the design of prospective trials.
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